Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Two-year data on methylphenidate in children with ADHD show reassuring findings on growth and psychiatric risks — but modest cardiovascular changes warrant regular monitoring. A separate study also finds that medication alone can't close academic learning gaps, underscoring the need for educational support alongside treatment.
Good news for parents worried about long-term ADHD medication: two-year data from the ADDUCE study show that methylphenidate — the most commonly prescribed ADHD drug in children — has little meaningful impact on growth and minimal psychiatric or neurologic side effects. Presented at the 39th Congress of the European College of Neuropsychopharmacology, the findings offer some of the most comprehensive real-world evidence yet on a drug now routinely used for up to two years or more.
That said, cardiovascular changes deserve attention. Blood pressure and heart rate rose modestly in children on methylphenidate, and a large Swedish study found that longer cumulative use was linked to higher cardiovascular disease risk — particularly hypertension. Clinicians are advised to check vitals before and after each dose adjustment and every six months.
On the academic front, a Norwegian study found that medication only narrowed the learning gap with non-ADHD peers by about 12%, suggesting targeted educational interventions are essential alongside pharmacotherapy.
Key Takeaways:
Why it matters: With ADHD medication use rising ~10% annually in high-income countries, clinicians need clear, long-term safety data to guide treatment decisions and reassure families.
